You’re offline. This is a read only version of the page.
Andrew is Head of Advice, Succession & Claims (Personal Risk
Professionals) however will be appearing in his capacity as an MPhil candidate
at NICM Health Research Institute, Western Sydney University.
Join us for a special member only session and provide input into a study being undertaken into endometriosis, insurance medicine and cannabinoid medicine.
The annual Australian cost burden of endometriosis stands at
$9.7Billion+ and impacts 1 in 9 women (& those assigned female at birth) or
830,000 people. Recent research has found that people with endometriosis in
Australia report using cannabis (or cannabinoid based medicinal products -
CBMPs) to help manage their endometriosis symptoms and significantly reduce
their other endometriosis-related medications (e.g. opioids; SSRIs).
It is uncertain how the use of CBMPs in symptomatic management of
medical conditions impacts on the ability for insureds to obtain, manage and
claim on financial products such as life, income protection, disability,
trauma, and private health insurance. This research seeks to find out about the
views of key stakeholders within life insurers, reinsurers and private health
insurers about their understanding, experiences, training, attitudes and risk
management perspectives on endometriosis (and cannabis use) in insurance
medicine settings. This project has been approved by the Western Sydney
University Ethics Committee (H15099).
Mr Andrew Proudfoot - LLB, BEcon, MTax(FP), Head of Advice, Succession & Claims at Personal Risk Professionals
This is an online event.
1 point(s) – Business, Technical and Specialist 